ED in APL: Tip of the iceberg?

Blood

Volumn 118, Issue 5, 2011, Pages 1188-1189

  Lo Coco, Francesco ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; RETINOIC ACID;

BLEEDING; CANCER CHEMOTHERAPY; CAUSE OF DEATH; CLINICAL TRIAL (TOPIC); DIAGNOSTIC ERROR; HEALTH CARE PERSONNEL; HUMAN; INFECTION; LONG TERM CARE; NOTE; POPULATION RESEARCH; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RELAPSE; SURVIVOR;

EID: 80051575068     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-06-361238     Document Type: Note

References (6)

1. Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leucemia remains high despite all-trans retinoic acid. Blood. 2011;118(5):1248-1254.
2. Sanz MA, Lo-Coco F. Modern approaches to treating acute promyelocytic leukemia. J Clin Oncol. 2011;29(5):495-503.
3. Wang ZY, Chen Z. Acute promyelocytic leucemia: from highly fatal to highly curable. Blood. 2008;111(5): 2505-2515.
4. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875-1891.
5. Lehmann S, Ravn A, Carlsson L, et al. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry. Leukemia. 2011;25(7):1128-1134.
6. de la Serna J, Montesinos P, Vellenga E, et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with alltrans retinoic acid and idarubicin. Blood. 2008;111(7):3395-3402.